Subject: VICL (Vical Labs)
| Previous | Next | Respond |
To: Tony T. ( 73 )
From: Tony T. Sep 13 1996 8:16AM EST
Reply #74
SAN DIEGO (Sept. 12) BUSINESS WIRE -Sept. 12, 1996--Vical Inc. (Nasdaq:VICL)announced today that the company is collaborating with Stanford University Medical Center (Palo Alto, Calif.) professor Ronald Levy, M.D. to proceed toward clinical trials with a potential DNA protective vaccine against B-cell lymphoma.
The vaccine would use Vical's proprietary "naked" DNA technology to deliver a gene that may cause muscle cells in the body to produce a substance (idiotypic determinant, or Id) unique to the target tumor cells.
The body's immune system may then produce anti-Id antibodies and T-cells which may eliminate residual cancer cells and potentially prevent disease relapse. In the September issue of Nature Medicine (2:9, 1038-1041) Levy et.al. disclose the results of the B-cell lymphoma DNA vaccine technology in a preclinical model.
B-cell lymphoma is a cancerous growth of certain cells of the immune system. More than 40,000 new cases occur yearly in the United States, most of which are ultimately fatal.
Vical has pioneered the use of "naked" DNA for vaccines against infectious diseases. The company's proprietary technology for DNA immunization is currently under license or option to Merck and Pasteur Merieux for a total of 13 infectious disease targets. Merck initiated clinical trials in May 1996 with a potential DNA vaccine against influenza.
This press release contains forward-looking statement that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether any product candidates will be developed and, if so, whether they will be shown to be safe and efficacious in clinical trials and the risks set forth in the Company's filings with the Securities and Exchange Commission. Actual results may differ materially from those projected. These forward-looking statements
represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward looking statements.
Vical Incorporated is focused on the development of gene-based pharmaceutical products for human therapy. Vical's gene-based therapeutic approach may offer safer and more cost-effective alternatives for many diseases, including infectious diseases, autoimmune disorders and cancer.
--30--mhu/la at/la
CONTACT: Vical Inc.
Alan R. Engbring, Director, Investor Relations
Robert H. Zaugg, Vice President, Business Development
619/453-9900
KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: MEDICINE BIOTECHNOLOGY PHARMACEUTICAL REPEATS: New York
212-752-9600 or 800-221-2462; Boston 617-236-4266 or 800-225-2030; SF
415-986-4422 or 800-227-0845; LA 310-820-9473 Today's News On The Net - Business
Wire's full file on the Internet with Hyperlinks to your home page. URL:
businesswire.com
Regis, I found this in an old vicl link. I don't know if you are interested but I thought I would post it anyway.
Oliver
| Previous | Next | Respond |
| Return to Biotech/Medical | View Bookmarks | Bookmark this Subject |
<Picture>
Send questions and feedback to webmaster@techstocks.com |
